

U.S. Application No. 09/936,205

**AMENDMENTS TO THE CLAIMS**

*Please amend claims as follows:*

Claims 1-8. (Cancelled).

9. (Currently amended) A method for preparing an organ by perfusion prior to transplantation or storage of the organ comprising:

(I) providing an ischemic reperfusion injury prevention preparation for perfusion of an organ prior to transplantation or storage of the organ, wherein the ischemic reperfusion injury prevention preparation comprises:

(A) a soluble derivative of a soluble polypeptide, wherein the soluble derivative comprises:

(1) a fragment of complement receptor 1 (CR1), wherein the fragment has having a sequence that is set forth in SEQ ID NO: 1 and has an immunoregulatory activity, and

(2) at least two membrane binding elements, wherein (a) at least one membrane binding element is a non-peptidic membrane binding element comprising acyl groups, and (b) at least one membrane binding element is a peptidic membrane binding element comprising basic amino acids, wherein the peptidic

U.S. Application No. 09/936,205

membrane binding element is bound to the non-peptidic membrane binding element and the fragment of complement receptor 1; and

(B) a physiologically acceptable and non-reducing flush storage solution;

and

(II) (C) perfusing the organ with the ischemic reperfusion injury prevention preparation, wherein the organ contains the ischemic reperfusion injury prevention preparation while isolated and prior to implantation.

Claims 10-13. (Canceled).

14. (Currently amended) The method according to claim 9, wherein the physiologically acceptable and non-reducing flush storage solution comprises potassium citrate, sodium citrate, mannitol and magnesium sulphate.

15. (Canceled).

16. (Previously presented) The method according to claim 9, wherein the fragment of complement receptor 1 (CR1) has a sequence according to positions 2 to 197 of SEQ ID NO.1.

17. (Previously presented) The method according to claim 9, wherein the peptidic membrane binding element comprises a sequence selected from the

U.S. Application No. 09/936,205

group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11.

18. (Previously presented) The method according to claim 9, wherein the non-peptidic membrane binding element comprises myristoyl.

19. (Currently amended) The method according to claim 9, wherein the organ is a kidney, a heart, a liver, or a lung.

20. (Previously presented) The method according to claim 19, wherein the organ is a human organ.

21. (Previously presented) The method according to claim 19, wherein the organ is a non-human animal organ.

22. (Previously presented) The method according to claim 9, wherein the peptidic membrane binding element comprises 8 to 20 amino acids.

23. (New) The method according to claim 9, wherein the immunoregulatory activity is a complement inhibitory activity.

24. (New) The method according to claim 14, wherein the physiologically acceptable flush storage solution is SOLTRAN.